Literature DB >> 25332229

Relationship between expression of matrix metalloproteinase-9 and adenylyl cyclase-associated protein 1 in chronic obstructive pulmonary disease.

Shuan-Shuan Xie1, Feng Hu2, Min Tan1, Yu-Xiang Duan3, Xiao-Lian Song1, Chang-Hui Wang4.   

Abstract

OBJECTIVE: To investigate the relationship between expression of matrix metalloproteinase (MMP)-9 and expression of adenylyl cyclase-associated protein (CAP)-1 in chronic obstructive pulmonary disease (COPD).
METHODS: Patients with possible respiratory disease were recruited into the study and divided into a COPD group and a non-COPD group on diagnosis. Pulmonary function tests were performed and serum concentrations of MMP-9 were measured using an enzyme-linked immunosorbent assay. MMP-9 and CAP1 expression were analysed in lung tissue and bronchoalveolar lavage fluid in all available samples using immunohistochemistry and Western blot, respectively. In addition, expression of MMP-9 and CAP1 in vitro was investigated using immunofluorescence. Expression of CAP1 in response to MMP-9 was measured in the human alveolar epithelial cell line HP-AEpiC, using Western blot.
RESULTS: A total of 90 patients were included in the study: 52 were in the COPD group and 38 in the non-COPD group. Serum MMP-9 concentrations were significantly higher in the COPD than in the non-COPD group. MMP-9 serum concentrations were negatively correlated with forced expiratory volume in 1 s (FEV1), FEV1 as a percentage of the normal predicted value and the ratio of FEV1 to forced vital capacity, and were positively correlated with residual volume (RV), total lung capacity (TLC) and RV/TLC values. In lung tissue and bronchoalveolar lavage fluid samples, MMP-9 and CAP1 expression were inversely related. This relationship was confirmed in HP-AEpiC cells. High expression of MMP-9 and low expression of CAP1 was demonstrated in the COPD group compared with the non-COPD group.
CONCLUSIONS: This study demonstrated an inverse relationship between CAP1 and MMP-9 expression, and high expression of MMP-9 and low expression of CAP1 in those with COPD compared with the non-COPD group. Overexpression of MMP-9 in lung tissue and its interaction with CAP1 is likely to play a major role in airway obstruction in COPD.
© The Author(s) 2014 Reprints and permissions: sagepub.co.uk/journalsPermissions.nav.

Entities:  

Keywords:  Matrix metalloproteinase-9; adenylyl cyclase-associated protein 1; chronic obstructive pulmonary disease

Mesh:

Substances:

Year:  2014        PMID: 25332229     DOI: 10.1177/0300060514548290

Source DB:  PubMed          Journal:  J Int Med Res        ISSN: 0300-0605            Impact factor:   1.671


  4 in total

Review 1.  GPNMB contributes to a vicious circle for chronic obstructive pulmonary disease.

Authors:  Xi-Juan Zhang; Zhong-Hua Cui; Yan Dong; Xiu-Wen Liang; Yan-Xin Zhao; Ancha Baranova; Hongbao Cao; Ling Wang
Journal:  Biosci Rep       Date:  2020-06-26       Impact factor: 3.840

2.  Cigarette smoke exposure decreases CFLAR expression in the bronchial epithelium, augmenting susceptibility for lung epithelial cell death and DAMP release.

Authors:  Alen Faiz; Irene H Heijink; Cornelis J Vermeulen; Victor Guryev; Maarten van den Berge; Martijn C Nawijn; Simon D Pouwels
Journal:  Sci Rep       Date:  2018-08-20       Impact factor: 4.379

3.  Elevated Matrix Metalloproteinase Levels in Bronchi Infected with Periodontopathogenic Bacteria.

Authors:  Luca Bernasconi; Liza L Ramenzoni; Ahmed Al-Majid; Gabrielo M Tini; Sereina M Graber; Patrick R Schmidlin; Sarosh Irani
Journal:  PLoS One       Date:  2015-12-14       Impact factor: 3.240

4.  Resistin upregulates chemokine production by fibroblast-like synoviocytes from patients with rheumatoid arthritis.

Authors:  Hiroshi Sato; Sei Muraoka; Natsuko Kusunoki; Shotaro Masuoka; Soichi Yamada; Hideaki Ogasawara; Toshio Imai; Yoshikiyo Akasaka; Naobumi Tochigi; Hiroshi Takahashi; Kazuaki Tsuchiya; Shinichi Kawai; Toshihiro Nanki
Journal:  Arthritis Res Ther       Date:  2017-12-01       Impact factor: 5.156

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.